AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36320050 — intervention group
Group type: EXPERIMENTAL
Intervention: Q-value customized ablation
Number of subjects: 40
Study 36320050 — intervention group
Group type: COMPARATOR
Intervention: Wavefront-optimized (WFO) ablation
Number of subjects: 40
Study 36321279 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) intervention
Number of subjects: 312
Study 36321279 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 312
Study 36321445 — intervention group
Group type: EXPERIMENTAL
Intervention: Device designed to enhance fluid and salt loss via eccrine sweat glands
Number of subjects: 24
Study 36321601 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual quantitative flow ratio (rQFR) after virtual percutaneous coronary intervention (vPCI)
Number of subjects: 274
Study 36321601 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-PCI fractional flow reserve (FFR)
Number of subjects: 274
Study 36321601 — intervention group
Group type: EXPERIMENTAL
Intervention: rQFR ≤0.89
Number of subjects: 274
Study 36321601 — intervention group
Group type: EXPERIMENTAL
Intervention: Target vessel revascularization
Number of subjects: 274
Study 36321894 — intervention group
Group type: EXPERIMENTAL
Intervention: High-level methanogen microbiota
Number of subjects: 82
Study 36321894 — intervention group
Group type: COMPARATOR
Intervention: Low-level methanogen microbiota
Number of subjects: 82
Study 36321894 — intervention group
Group type: EXPERIMENTAL
Intervention: Methanogen levels
Number of subjects: 82
Study 36321894 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogenotrophic functional groups
Number of subjects: 82
Study 36321894 — intervention group
Group type: EXPERIMENTAL
Intervention: Copy numbers of genes indicative of total bacteria and acetogens
Number of subjects: 82
Study 36322113 — intervention group
Group type: EXPERIMENTAL
Intervention: MindShift CBT app plus treatment as usual (TAU) over 6 days
Number of subjects: 20
Study 36322113 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 20
Study 36322396 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Functional Mobilization (EFM)
Number of subjects: 47
Study 36322396 — intervention group
Group type: COMPARATOR
Intervention: Standard Treatment (ST)
Number of subjects: 47
Study 36322537 — intervention group
Group type: EXPERIMENTAL
Intervention: MIS-C children
Number of subjects: 0
Study 36322537 — intervention group
Group type: EXPERIMENTAL
Intervention: MIS-C children post-recovery (6-9 months)
Number of subjects: 0
Study 36322537 — intervention group
Group type: COMPARATOR
Intervention: Other syndromes (non-MIS-C conditions)
Number of subjects: 0
Study 36322608 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression symptoms
Number of subjects: 1818
Study 36322608 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient activation
Number of subjects: 1818
Study 36322627 — intervention group
Group type: EXPERIMENTAL
Intervention: Regulatory T cells (Tregs)
Number of subjects: 0
Study 36322627 — intervention group
Group type: COMPARATOR
Intervention: Immunosuppressive drugs
Number of subjects: 0
Study 36322714 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow-derived, allogeneic MSCs (75 million MSCs administered via direct injection, with repeat injection at 3 months if needed)
Number of subjects: 22
Study 36322714 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MSC therapy)
Number of subjects: 22
Study 36322782 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week mobile health (mHealth) prescription to monitor for AF recurrences
Number of subjects: 335
Study 36322825 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib/prednisone induction followed by blinatumomab/dasatinib postremission therapy for 3 cycles and dasatinib/prednisone maintenance.
Number of subjects: 24
Study 36322825 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab reinduction therapy for patients not achieving response by day 56.
Number of subjects: 24
Study 36322825 — intervention group
Group type: EXPERIMENTAL
Intervention: Central nervous system prophylaxis with intrathecal methotrexate for a total of 8 doses.
Number of subjects: 24
Study 36323235 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-963272 (MGAT2 inhibitor)
Number of subjects: 0
Study 36323235 — intervention group
Group type: COMPARATOR
Intervention: Selective DGAT1 inhibitor
Number of subjects: 0
Study 36323435 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) combination therapy
Number of subjects: 5000
Study 36323435 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICIs) targeting PD-1 and CTLA-4
Number of subjects: 5000
Study 36323435 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative systems pharmacology (QSP) model
Number of subjects: 5000
Study 36323444 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin with standard therapy
Number of subjects: 0
Study 36323464 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal antibiotic treatment during pregnancy
Number of subjects: 0
Study 36323464 — intervention group
Group type: EXPERIMENTAL
Intervention: C-section mode of delivery
Number of subjects: 0
Study 36323464 — intervention group
Group type: COMPARATOR
Intervention: Vaginal delivery
Number of subjects: 0
Study 36323479 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal pre-pregnancy BMI
Number of subjects: 200
Study 36323480 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher gestational age
Number of subjects: 778
Study 36323480 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher socioeconomic status (SES)
Number of subjects: 778
Study 36323480 — intervention group
Group type: EXPERIMENTAL
Intervention: Older siblings
Number of subjects: 778
Study 36323480 — intervention group
Group type: EXPERIMENTAL
Intervention: Boys
Number of subjects: 778
Study 36323480 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural difficulties
Number of subjects: 778
Study 36323480 — intervention group
Group type: EXPERIMENTAL
Intervention: Age interactions
Number of subjects: 778
Study 36323480 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep duration, breastfeeding duration, overweight/obesity
Number of subjects: 778
Study 36323612 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib (first-line treatment)
Number of subjects: 152
Study 36324098 — intervention group
Group type: EXPERIMENTAL
Intervention: Skewed X chromosome inactivation (SXCI)
Number of subjects: 131
Study 36324098 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen receptor (AR) CAG repeats
Number of subjects: 131
Study 36324098 — intervention group
Group type: EXPERIMENTAL
Intervention: CAG repeat < 20, SXCI, and duration of stimulation
Number of subjects: 131
Study 36324098 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian reserve and preimplantation embryo aneuploidy
Number of subjects: 131
Study 36324098 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation cohort of 363 patients with RPL
Number of subjects: 131
Study 36324132 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialised Paediatric Palliative Care (SPPC) programme
Number of subjects: 0
Study 36324132 — intervention group
Group type: COMPARATOR
Intervention: Routine care in a generalised palliative care (PPC) environment
Number of subjects: 0
Study 36324132 — intervention group
Group type: EXPERIMENTAL
Intervention: SPPC programme
Number of subjects: 0
Study 36324191 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment for trigger finger
Number of subjects: 55
Study 36324326 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled-sample testing using the Allplex STI Essential Assay
Number of subjects: 130
Study 36325355 — intervention group
Group type: EXPERIMENTAL
Intervention: FCR treatment (fludarabine-cyclophosphamide-rituximab)
Number of subjects: 123
Study 36325385 — intervention group
Group type: EXPERIMENTAL
Intervention: Phased multidimensional intervention bundle
Number of subjects: 297
Study 36325385 — intervention group
Group type: COMPARATOR
Intervention: Retrospective control group
Number of subjects: 297
Study 36325389 — intervention group
Group type: EXPERIMENTAL
Intervention: KIO-100 (PP-001), a small molecule DHODH-inhibitor
Number of subjects: 0
Study 36325389 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 36325895 — intervention group
Group type: EXPERIMENTAL
Intervention: PCAT attenuation in ACS patients
Number of subjects: 471
Study 36325895 — intervention group
Group type: COMPARATOR
Intervention: PCAT attenuation in SAP patients
Number of subjects: 471
Study 36325895 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of PCAT attenuation
Number of subjects: 471
Study 36326077 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational group programme
Number of subjects: 19
Study 36326139 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal voluntary pelvic floor muscle contractions ≥3 (Modified Oxford Scale, scored from 0 to 5)
Number of subjects: 504
Study 36326139 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastasis recti abdominis width ≥35 mm
Number of subjects: 504
Study 36326139 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastasis recti abdominis width
Number of subjects: 504
Study 36326435 — intervention group
Group type: COMPARATOR
Intervention: Avoralstat
Number of subjects: 912
Study 36326435 — intervention group
Group type: COMPARATOR
Intervention: Berotralstat
Number of subjects: 912
Study 36326435 — intervention group
Group type: COMPARATOR
Intervention: C1-INH (all forms)
Number of subjects: 912
Study 36326435 — intervention group
Group type: COMPARATOR
Intervention: Lanadelumab
Number of subjects: 912
Study 36326435 — intervention group
Group type: COMPARATOR
Intervention: Danazol
Number of subjects: 912
Study 36326435 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous C1-INH
Number of subjects: 912
Study 36326435 — intervention group
Group type: COMPARATOR
Intervention: Plasma-derived C1-INH
Number of subjects: 912
Study 36326435 — intervention group
Group type: COMPARATOR
Intervention: Nanofiltered C1-INH
Number of subjects: 912
Study 36326435 — intervention group
Group type: COMPARATOR
Intervention: Recombinant human C1-INH
Number of subjects: 912
Study 36326435 — intervention group
Group type: COMPARATOR
Intervention: C1-INH (all forms), Berotralstat, Lanadelumab
Number of subjects: 912
Study 36326435 — intervention group
Group type: COMPARATOR
Intervention: Adverse events (including serious adverse events)
Number of subjects: 912
Study 36326435 — intervention group
Group type: COMPARATOR
Intervention: Mortality
Number of subjects: 912
Study 36326473 — intervention group
Group type: EXPERIMENTAL
Intervention: Inorganic nitrate/nitrite supplementation for 8 weeks
Number of subjects: 0
Study 36326473 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 36326731 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy (IO)
Number of subjects: 12046
Study 36326731 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-immunotherapy systemic anticancer therapies (non-IO)
Number of subjects: 12046
Study 36326731 — intervention group
Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 12046
Study 36326797 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC)
Number of subjects: 20
Study 36326854 — intervention group
Group type: EXPERIMENTAL
Intervention: ePRO system for AA and PNH patients
Number of subjects: 9
Study 36326921 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial NPWT in America (77.4%) and Europe (52.3%)
Number of subjects: 1183
Study 36326921 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitive abdominal closure in America (82.3%, fascial closure in 90.2%)
Number of subjects: 1183
Study 36326921 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosthesis use in Europe (17.3%)
Number of subjects: 1183
Study 36326921 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall morbidity rates
Number of subjects: 1183
Study 36326921 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality rates
Number of subjects: 1183
Study 36326921 — intervention group
Group type: EXPERIMENTAL
Intervention: Median open abdomen duration
Number of subjects: 1183
Study 36326921 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall ICU length-of-stay
Number of subjects: 1183
Study 36326921 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall hospital length-of-stay
Number of subjects: 1183
Study 36326921 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall entero-atmospheric fistula rate
Number of subjects: 1183
Study 36327059 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI + PWI ablation strategy with mandatory repeat procedures
Number of subjects: 24
Study 36327094 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg (FIL200)
Number of subjects: 1755
Study 36327094 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 100 mg (FIL100)
Number of subjects: 1755
Study 36327094 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab (ADA)
Number of subjects: 1755
Study 36327094 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 1755
Study 36327094 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib (FIL)
Number of subjects: 1755
Study 36327344 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof IQ PanOptix trifocal IOL (TFNT00)
Number of subjects: 2
Study 36327344 — intervention group
Group type: COMPARATOR
Intervention: AcrySof monofocal IOL (SN60AT)
Number of subjects: 2
Study 36327378 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-Based Treatment delivered by videoconferencing (FBT-V)
Number of subjects: 21
Study 36327624 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd)
Number of subjects: 0
Study 36327624 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab emtansine (T-DM1)
Number of subjects: 0
Study 36328033 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab plus FOLFOX (intravenous trastuzumab-pkrb at 6 mg/kg on day 1, FOLFOX regimen with intravenous oxaliplatin [85 mg/m2])
Number of subjects: 34
Study 36328033 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab plus FOLFOX
Number of subjects: 34
Study 36328377 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for four doses, followed by nivolumab 480 mg every 4 weeks for up to 2 years or until progression, toxicity, or protocol-specified discontinuation.
Number of subjects: 46
Study 36328378 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study 36328388 — intervention group
Group type: EXPERIMENTAL
Intervention: Audible waveform assessment
Number of subjects: 730
Study 36328388 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual waveform assessment
Number of subjects: 730
Study 36328388 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle brachial pressure index (ABPI)
Number of subjects: 730
Study 36328388 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise ABPI
Number of subjects: 730
Study 36328388 — intervention group
Group type: EXPERIMENTAL
Intervention: Toe brachial pressure index (TBPI)
Number of subjects: 730
Study 36328388 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care duplex ultrasound scan (PAD-scan)
Number of subjects: 730
Study 36328388 — intervention group
Group type: COMPARATOR
Intervention: Reference tests (CT angiography or magnetic resonance angiography)
Number of subjects: 730
Study 36328399 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dose primary SARS-CoV-2 vaccination in patients with IMID
Number of subjects: 1100
Study 36328399 — intervention group
Group type: COMPARATOR
Intervention: Two-dose primary SARS-CoV-2 vaccination in healthy controls
Number of subjects: 1100
Study 36328399 — intervention group
Group type: EXPERIMENTAL
Intervention: Third dose of vaccination
Number of subjects: 1100
Study 36328399 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of antibody decline rates
Number of subjects: 1100
Study 36328399 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events in patients with IMID
Number of subjects: 1100
Study 36328399 — intervention group
Group type: COMPARATOR
Intervention: Adverse events in healthy controls
Number of subjects: 1100
Study 36328399 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease flares in patients with IMID
Number of subjects: 1100
Study 36328395 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 25
Study 36328395 — intervention group
Group type: EXPERIMENTAL
Intervention: Desethylhydroxychloroquine (DHCQ)
Number of subjects: 25
Study 36328438 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent inactivated influenza vaccine
Number of subjects: 0
Study 36328438 — intervention group
Group type: COMPARATOR
Intervention: Trivalent inactivated influenza vaccines
Number of subjects: 0
Study 36328690 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention
Number of subjects: 40670
Study 36328690 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blockers
Number of subjects: 40670
Study 36328690 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 40670
Study 36328690 — intervention group
Group type: COMPARATOR
Intervention: In-hospital mortality for IHCA patients
Number of subjects: 40670
Study 36328690 — intervention group
Group type: COMPARATOR
Intervention: IHCA as a percentage of inpatient deaths
Number of subjects: 40670
Study 36328851 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone and case management services
Number of subjects: 32
Study 36328851 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone continuation after trial
Number of subjects: 32
Study 36328851 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline daily alcohol consumption
Number of subjects: 32
Study 36328851 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline quality of life
Number of subjects: 32
Study 36328903 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab maintenance therapy
Number of subjects: 0
Study 36328903 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 0
Study 36329042 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal pathobionts (specifically Porphyromonas gingivalis)
Number of subjects: 0
Study 36329070 — intervention group
Group type: EXPERIMENTAL
Intervention: Females on dialysis
Number of subjects: 4994
Study 36329070 — intervention group
Group type: COMPARATOR
Intervention: Males on dialysis
Number of subjects: 4994
Study 36329070 — intervention group
Group type: COMPARATOR
Intervention: All-cause mortality for females vs males
Number of subjects: 4994
Study 36329070 — intervention group
Group type: COMPARATOR
Intervention: Mortality due to sudden death, cancer, other, or unknown causes for females vs males
Number of subjects: 4994
Study 36329070 — intervention group
Group type: COMPARATOR
Intervention: Mortality in patients on HD (females vs males)
Number of subjects: 4994
Study 36329070 — intervention group
Group type: COMPARATOR
Intervention: Mortality in patients on PD (females vs males)
Number of subjects: 4994
Study 36329083 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor imagery training (MIT) of goal-directed reaching for four weeks.
Number of subjects: 27
Study 36329366 — intervention group
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Number of subjects: 55
Study 36329414 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led anthropometric and oropharyngeal measurements combined with STOP-Bang questionnaire
Number of subjects: 761
Study 36329414 — intervention group
Group type: COMPARATOR
Intervention: STOP-BANG Questionnaire (SBQ)
Number of subjects: 761
Study 36329414 — intervention group
Group type: COMPARATOR
Intervention: Waist circumference
Number of subjects: 761
Study 36329414 — intervention group
Group type: COMPARATOR
Intervention: Micrognathia
Number of subjects: 761
Study 36329512 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe OSA (apnoea-hypopnea index ≥30/h)
Number of subjects: 103
Study 36329512 — intervention group
Group type: EXPERIMENTAL
Intervention: STOP-Bang questionnaire
Number of subjects: 103
Study 36329512 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipidomic profiling
Number of subjects: 103
Study 36330013 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (including drug-coated balloon, directional atherectomy, supera, and drug-eluting stent)
Number of subjects: 600
Study 36330105 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec/insulin aspart (IDegAsp)
Number of subjects: 0
Study 36330105 — intervention group
Group type: COMPARATOR
Intervention: Biphasic insulin aspart 30 (BIAsp 30)
Number of subjects: 0
Study 36330140 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain wheat (WGW) intervention (98 g/d)
Number of subjects: 50
Study 36330140 — intervention group
Group type: COMPARATOR
Intervention: Refined wheat (RW) intervention
Number of subjects: 50
Study 36330140 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain wheat (WGW) intervention
Number of subjects: 50
Study 36330484 — intervention group
Group type: EXPERIMENTAL
Intervention: Buparlisib, an oral pan-PI3K inhibitor, administered for a median of 4.5 months (range 2-33).
Number of subjects: 14
Study 36330484 — intervention group
Group type: EXPERIMENTAL
Intervention: Buparlisib, an oral pan-PI3K inhibitor.
Number of subjects: 14
Study 36330490 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib 500 mg
Number of subjects: 60
Study 36330490 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib 750 mg
Number of subjects: 60
Study 36330490 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib 850 mg
Number of subjects: 60
Study 36330525 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginase-1 peptide vaccine (three 20-mer peptides from the ARG1 immunological 'hot spot' region with Montanide ISA-51 adjuvant, administered subcutaneously every third week, maximum 16 vaccines)
Number of subjects: 10
Study 36330525 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginase-1 peptide vaccine
Number of subjects: 10
Study 36331157 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy-guided lymph node dissection
Number of subjects: 162
Study 36331157 — intervention group
Group type: COMPARATOR
Intervention: Extended pelvic lymph node dissection (reference standard)
Number of subjects: 162
Study 36331190 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 6609
Study 36331190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6609